Brind.
  1. Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer.

Ligand Pharmaceuticals appointed Todd Davis as CEO, acquired a 56% stake in Pelthos Therapeutics Inc., and secured royalty rights on ZELSUVMI sales.

4 reports, 2 independent Updated Thu 00:00
Mostly repetition
Reports
4
Developments
2
Repetition
75%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 2 outlets

Ligand Pharmaceuticals appointed Todd Davis as CEO, acquired a 56% stake in Pelthos Therapeutics Inc., and secured royalty rights on ZELSUVMI sales.

Who's involved

What this event is mainly about
Ligand PharmaceuticalsTodd Davis

How it developed

Newest first. Tap a step to see who reported it.
  1. Ligand Pharmaceuticals' subsidiary LNHC and Pelthos Therapeutics formed a merger.Sub-event
  2. Ligand appoints CEO Todd Davis and acquires 56% of Pelthos Therapeutics Inc.1 source

Keep exploring

Part of

Ligand Pharmaceuticals formed drug development partnerships with Amgen, Merck KGaA, and Pfizer. All 2 developments

The entities involved

Coverage

Newest first; wire copies grouped
  • manilatimes.net
  • GlobeNewswireLigand Partner Pelthos Therapeutics Launches ZELSUVMI™ JUPITER, Fla., July 10, 2025 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Pelthos The
  • Unknown outlet
1 more outlet ran the same wire story